Legend Biotech (LEGN) CEO details initial share and option holdings
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Legend Biotech Corp Chief Executive Officer Huang Ying filed an initial ownership report showing direct holdings of 257,374 Ordinary Shares. This total includes 43,010 restricted share units, with 28,119 shares scheduled to vest on March 20, 2026 and 14,891 on June 20, 2026, subject to continued service.
Huang also reports multiple share options over Ordinary Shares at exercise prices from $1.5000 to $27.5000, expiring between July 21, 2029 and April 2, 2033. Footnotes state that some options are immediately exercisable, while others vest on April 3, 2026. Each American Depositary Share represents two Ordinary Shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
9 transactions reported
Mixed
9 txns
Insider
Huang Ying
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Share Option (right to buy) — 81,788 shares (Direct);
Ordinary Shares — 257,374 shares (Direct)
Footnotes (1)
- The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer. Includes 43,010 restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 28,119 shares underlying the RSU will vest on March 20, 2026 and the remaining 14,891 shares will vest on June 20, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date. All of the shares subject to the option are immediately exercisable. All of the shares subject to the option shall vest on April 3, 2026. 40,000 of the shares subject to the option are immediately exercisable and the remainder shall vest on April 3, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
FAQ
What does Huang Ying report owning in Legend Biotech (LEGN) on this Form 3?
Huang Ying reports direct ownership of 257,374 Ordinary Shares of Legend Biotech. This amount includes 43,010 restricted share units that convert into ordinary shares upon vesting, plus several option grants over additional Ordinary Shares at specified exercise prices and expirations.
What stock options are reported by the Legend Biotech CEO on this Form 3?
Huang Ying reports multiple share options over Ordinary Shares. Examples include options over 121,746 shares at an exercise price of $1.5000 expiring on July 21, 2029, and 185,340 shares at $27.5000 expiring on June 29, 2032.
Are any of the Legend Biotech CEO’s options immediately exercisable?
Yes. A footnote states that all shares subject to one option grant are immediately exercisable. Another grant provides that 40,000 shares are immediately exercisable, with the remaining option shares vesting on April 3, 2026, subject to continued service.
Does this Legend Biotech Form 3 show any insider buying or selling activity?
No specific buy or sell transactions are reported. The Form 3 presents Huang Ying’s existing holdings in Ordinary Shares, restricted share units, and share options as of the reporting date, rather than documenting new purchases or sales in the market.